The FDA’s recently published roadmap to phasing out animal use in preclinical safety testing marks a pivotal moment in regulatory science. By formally endorsing New Approach Methodologies (NAMs), from spheroids, organoids, organ-on-chip platforms to AI-based modeling, the FDA Roadmap sets the stage for a more human-relevant, predictive, and ethically responsible paradigm in drug development.
What we celebrate about the FDA Roadmap:
✅ Clear regulatory recognition of human-relevant models
The FDA roadmap explicitly acknowledges that animal models often fail to predict human responses, particularly in complex diseases like cancer or immunology. This formal shift in thinking is essential to open regulatory doors for spheroids, organoids, microphysiological systems, and computational tools.
✅ A well-structured implementation timeline
From focusing initially on monoclonal antibodies to creating open-access databases and exploring case-specific waivers, the roadmap outlines actionable, phased strategies for integrating NAMs into regulatory decision-making.
✅ Interagency coordination and public-private collaboration
By leveraging platforms like ICCVAM and partnering with NIH and industry, the FDA is laying the groundwork for harmonized validation and qualification of NAMs, which is an essential step for global credibility and industry adoption.
🧩 What we feel is still missing or needs strengthening (of course acknowledging that the roadmap’s focus is safety):
❌ Limited focus on drug discovery and early de-risking
While the FDA roadmap emphasizes safety assessment, there’s little mention of how NAMs can add value in discovery, e.g., by improving candidate triage through mechanistic insights or modeling patient diversity. This could also be very relevant for repurposing or combination therapies.
❌ No framework for economic incentives or funding mechanisms
Accelerating adoption will require more than scientific rigor – it demands aligned incentives. Pilot funding, regulatory fee relief, or fast-track review pathways for NAM-enabled submissions could help innovators take the leap.
❌ Unclear strategy for global harmonization
To truly shift industry behavior, regulators must align internationally. Although ICH revision is mentioned, the new FDA roadmap lacks a concrete plan for engaging EMA, PMDA, and other key agencies to create globally accepted standards.
As the industry continues to embrace 3D in vitro and in silico systems, the new FDA roadmap is a welcome catalyst. But to achieve scalable impact, we must now move from intention to execution. And do so collaboratively.
